180 related articles for article (PubMed ID: 38622716)
1. Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization.
Sun X; Nong M; Meng F; Sun X; Jiang L; Li Z; Zhang P
J Transl Med; 2024 Apr; 22(1):353. PubMed ID: 38622716
[TBL] [Abstract][Full Text] [Related]
2. The genetic algorithm-aided three-stage ensemble learning method identified a robust survival risk score in patients with glioma.
Zhu S; Kong W; Zhu J; Huang L; Wang S; Bi S; Xie Z
Brief Bioinform; 2022 Sep; 23(5):. PubMed ID: 36088543
[TBL] [Abstract][Full Text] [Related]
3. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
4. Identification of disulfidptosis-related subgroups and prognostic signatures in lung adenocarcinoma using machine learning and experimental validation.
Wang Y; Xu Y; Liu C; Yuan C; Zhang Y
Front Immunol; 2023; 14():1233260. PubMed ID: 37799714
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
Front Immunol; 2022; 13():906889. PubMed ID: 35757722
[TBL] [Abstract][Full Text] [Related]
6. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
8. Immune, metabolic landscapes of prognostic signatures for lung adenocarcinoma based on a novel deep learning framework.
Qin S; Sun S; Wang Y; Li C; Fu L; Wu M; Yan J; Li W; Lv J; Chen L
Sci Rep; 2024 Jan; 14(1):527. PubMed ID: 38177198
[TBL] [Abstract][Full Text] [Related]
9. A gene-based score for the risk stratification of stage IA lung adenocarcinoma.
Xiong Y; Ma Y; Liu K; Lei J; Zhao J; Zhu J; Wang W; Wen M; Wang X; Sun Y; Zhao Y; Han Y; Jiang T; Liu Y
Respir Res; 2024 Jan; 25(1):18. PubMed ID: 38178073
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
11. Single-cell dissection reveals the role of aggrephagy patterns in tumor microenvironment components aiding predicting prognosis and immunotherapy on lung adenocarcinoma.
Sun X; Meng F; Nong M; Fang H; Lu C; Wang Y; Zhang P
Aging (Albany NY); 2023 Dec; 15(23):14333-14371. PubMed ID: 38095634
[TBL] [Abstract][Full Text] [Related]
12. A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma.
Liu C; Wang S; Zheng S; Wang X; Huang J; Lei Y; Mao S; Feng X; Sun N; He J
Cancer Biol Med; 2021 Apr; 18(3):734-49. PubMed ID: 33856140
[TBL] [Abstract][Full Text] [Related]
13. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
Li Z; Guo M; Lin W; Huang P
Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
[TBL] [Abstract][Full Text] [Related]
14. Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma.
Zhang P; Pei S; Wu L; Xia Z; Wang Q; Huang X; Li Z; Xie J; Du M; Lin H
Front Endocrinol (Lausanne); 2023; 14():1196372. PubMed ID: 37265698
[TBL] [Abstract][Full Text] [Related]
15. [Construction and Validation of Prognostic Risk Score Model of Autophagy Related Genes in Lung Adenocarcinoma].
Zhou J; Wang X; Li Z; Jiang R
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):557-566. PubMed ID: 34256900
[TBL] [Abstract][Full Text] [Related]
16. Machine learning-based immune prognostic model and ceRNA network construction for lung adenocarcinoma.
He X; Su Y; Liu P; Chen C; Chen C; Guan H; Lv X; Guo W
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7379-7392. PubMed ID: 36939925
[TBL] [Abstract][Full Text] [Related]
17. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
18. Establishment and validation of an eight-gene metabolic-related prognostic signature model for lung adenocarcinoma.
Ma W; Liang J; Liu J; Tian D; Chen Z
Aging (Albany NY); 2021 Feb; 13(6):8688-8705. PubMed ID: 33619235
[TBL] [Abstract][Full Text] [Related]
19. Identification Six Metabolic Genes as Potential Biomarkers for Lung Adenocarcinoma.
Zhang S; Lu Y; Liu Z; Li X; Wang Z; Cai Z
J Comput Biol; 2020 Oct; 27(10):1532-1543. PubMed ID: 32298601
[TBL] [Abstract][Full Text] [Related]
20. Insight of a Metabolic Prognostic Model to Identify Tumor Environment and Drug Vulnerability for Lung Adenocarcinoma.
Peng SL; Wang R; Zhou YL; Wei W; Zhong GH; Huang XT; Yang S; Liu QD; Liu ZG
Front Immunol; 2022; 13():872910. PubMed ID: 35812404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
